Trial intelligence / Profile preview

Phase I/II study of single-dose XMVA09 in wet age-related macular degeneration

ChiCTR2400082972Phase 2Not yet recruiting

Sponsor: Tianjin Medical University General Hospital
Start: Apr 2024
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Countries: 1

Overview

Phase 2, open-label trial of XMVA09 in exudative macular degeneration, sponsored by Tianjin Medical University General Hospital. Primary endpoints: Safety and Dose-limiting toxicity. Planned start Apr 2024; status: not yet recruiting.

Drugs

XMVA09

Conditions

exudative macular degeneration

Beyond the preview

Go deeper on ChiCTR2400082972.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2400082972.